Resalis’ objective is to therapeutically support the body’s biology to tackle obesity and fatty liver disease and achieve long-lasting effects.
Metabolic syndromes are complex diseases regulated via multiple cellular pathways. MicroRNA miR-22 orchestrates multiple pro-lipogenic programs modulating both direct and indirect gene targets. Resalis has applied a cutting-edge locked nucleic acid (LNA) technology to design RES-010 so that it is tailored to target miR-22. The LNA approach also provides increased stability to RES-010 without affecting its bioavailability.
RES-010 inhibits miR-22 to:
- Restore regulation of lipid biosynthesis
- Promote metabolic rewiring towards higher energy expenditure
- Transform white adipose tissue into brown adipose tissue
- Reduce and prevent hepatic steatosis, fibrosis, and inflammation
- Induce weight loss
Binding and inhibition of miR-22 by RES-010 could ultimately improve a patient’s quality of life.
